Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Post-Exposure Prophylaxis | Research

Concordance between SARS-CoV-2 index individuals and their household contacts on index individual COVID-19 transmission cofactors: a comparison of self-reported and contact-reported information

Authors: Angela M. Dahl, Clare E. Brown, Elizabeth R. Brown, Meagan P. O’Brien, Ruanne V. Barnabas

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Following the outbreak of the COVID-19 pandemic, several clinical trials have evaluated postexposure prophylaxis (PEP) among close contacts of an index individual with a confirmed SARS-CoV-2 infection. Because index individuals do not directly inform the efficacy of prevention interventions, they are seldom enrolled in COVID-19 PEP studies. However, adjusting for prognostic covariates such as an index individual’s COVID-19 illness and risk behaviors can increase precision in PEP efficacy estimates, so approaches to accurately collecting this information about the index individual are needed. This analysis aimed to assess whether surveying household contacts captures the same information as surveying the index individual directly.

Methods

REGN 2069/CoVPN 3502, a randomized controlled trial of COVID-19 PEP, enrolled household contacts of SARS-CoV-2 index individuals. CoVPN 3502-01 retrospectively enrolled and surveyed the index individuals. We compared responses to seven similar questions about the index individuals’ transmission cofactors that were asked in both studies. We estimated the percent concordance between index individuals and their household contacts on each question, with 50% concordance considered equivalent to random chance.

Results

Concordance between index individuals and contacts was high on the most objective questions, approximately 97% (95% CI: 90–99%) for index individual age group and 96% (88–98%) for hospitalization. Concordance was moderate for symptoms, approximately 85% (75–91%). Concordance on questions related to the index individual’s behavior was only slightly better or no better than random: approximately 62% (51–72%) for whether they received COVID-19 treatment, 68% (57–77%) for sharing a bedroom, 70% (59–79%) for sharing a common room, and 49% (39–60%) for mask wearing at home. However, while contacts were surveyed within 96 h of the index individual testing positive for SARS-CoV-2, the median time to enrollment in CoVPN 3502-01 was 240 days, which may have caused recall bias in our results.

Conclusions

Our results suggest a need to survey index individuals directly in order to accurately capture their transmission cofactors, rather than relying on their household contacts to report on their behavior. The lag in enrolling participants into CoVPN 3502-01 also highlights the importance of timely enrollment to minimize recall bias.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barnabas RV, Brown ER, Bershteyn A et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial [published correction appears in Ann Intern Med. 2021;174(3):435]. Ann Intern Med, 2021;174(3):344-52. Barnabas RV, Brown ER, Bershteyn A et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial [published correction appears in Ann Intern Med. 2021;174(3):435]. Ann Intern Med, 2021;174(3):344-52.
2.
go back to reference O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184–95.CrossRefPubMed O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184–95.CrossRefPubMed
4.
go back to reference Alpizar SA, Accini J, Anderson DC, Eysa B, Medina-Piñón I, Ohmagari N, et al. Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial. J Infect. 2023;87:392–402.CrossRefPubMed Alpizar SA, Accini J, Anderson DC, Eysa B, Medina-Piñón I, Ohmagari N, et al. Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial. J Infect. 2023;87:392–402.CrossRefPubMed
5.
go back to reference Tan DHS, Chan AK, Jüni P, Tomlinson G, Daneman N, Walmsley S, et al. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials. 2021;22:224.CrossRefPubMedPubMedCentral Tan DHS, Chan AK, Jüni P, Tomlinson G, Daneman N, Walmsley S, et al. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials. 2021;22:224.CrossRefPubMedPubMedCentral
6.
go back to reference Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21(5):629–36.CrossRefPubMedPubMedCentral Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21(5):629–36.CrossRefPubMedPubMedCentral
7.
go back to reference Derqui N, Koycheva A, Zhou J, Pillay TD, Crone MA, Hakki S, et al. Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study. Lancet Microbe. 2023;4:e397–408.CrossRefPubMedPubMedCentral Derqui N, Koycheva A, Zhou J, Pillay TD, Crone MA, Hakki S, et al. Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study. Lancet Microbe. 2023;4:e397–408.CrossRefPubMedPubMedCentral
8.
go back to reference Namageyo-Funa A, Ruffin JD, Killerby ME, Jalloh MF, Scott C, Lindell K, et al. Behaviors Associated with Household Transmission of SARS-CoV-2 in California and Colorado, January 2021–April 2021. AJPM Focus. 2022;1:100004.CrossRefPubMedPubMedCentral Namageyo-Funa A, Ruffin JD, Killerby ME, Jalloh MF, Scott C, Lindell K, et al. Behaviors Associated with Household Transmission of SARS-CoV-2 in California and Colorado, January 2021–April 2021. AJPM Focus. 2022;1:100004.CrossRefPubMedPubMedCentral
9.
go back to reference Sun K, Loria V, Aparicio A, Porras C, Vanegas JC, Zúñiga M, et al. Behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica. Commun Med. 2023;3:102.CrossRefPubMedPubMedCentral Sun K, Loria V, Aparicio A, Porras C, Vanegas JC, Zúñiga M, et al. Behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica. Commun Med. 2023;3:102.CrossRefPubMedPubMedCentral
10.
go back to reference Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products: Guidance for Industry [Internet]. Silver Spring, MD: Food and Drug Administration; 2023 May [cited 4 Jan 2024]. Available from: https://www.fda.gov/media/148910/download. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products: Guidance for Industry [Internet]. Silver Spring, MD: Food and Drug Administration; 2023 May [cited 4 Jan 2024]. Available from: https://​www.​fda.​gov/​media/​148910/​download.
11.
go back to reference Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research. E6(R2.) Good Clinical Practice: Integrated Addendum to ICH E6(R1) [Internet]. Silver Spring, MD: Food and Drug Administration; 2018 Mar [cited 20 Dec 2023]. Available from: https://www.fda.gov/media/93884/download. Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research. E6(R2.) Good Clinical Practice: Integrated Addendum to ICH E6(R1) [Internet]. Silver Spring, MD: Food and Drug Administration; 2018 Mar [cited 20 Dec 2023]. Available from: https://​www.​fda.​gov/​media/​93884/​download.
12.
go back to reference ClinicalTrials.gov. COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay [Internet]. Bethesda, MD: U.S. National Library of Medicine. 2023 May 15 [cited 20 Dec 2023]. Available from: https://clinicaltrials.gov/study/NCT04452318. ClinicalTrials.gov. COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay [Internet]. Bethesda, MD: U.S. National Library of Medicine. 2023 May 15 [cited 20 Dec 2023]. Available from: https://​clinicaltrials.​gov/​study/​NCT04452318.
13.
go back to reference ClinicalTrials.gov. Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) (IICov19PRS) [Internet]. Bethesda, MD: U.S. National Library of Medicine. 2021 Dec 15 [cited 2022 Nov 9]. Available from: https://clinicaltrials.gov/study/NCT05074719. ClinicalTrials.gov. Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) (IICov19PRS) [Internet]. Bethesda, MD: U.S. National Library of Medicine. 2021 Dec 15 [cited 2022 Nov 9]. Available from: https://​clinicaltrials.​gov/​study/​NCT05074719.
14.
go back to reference O’Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med, 2021;385(13)(Suppl Protocol). O’Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med, 2021;385(13)(Suppl Protocol).
15.
go back to reference Williams EL, Pierre DL, Martin ME, Beg MS, Gerber DE. Taking Tele behind the scenes: remote clinical trial monitoring comes of Age during the COVID-19 pandemic. JCO Oncol Pr. 2021;17:577–9.CrossRef Williams EL, Pierre DL, Martin ME, Beg MS, Gerber DE. Taking Tele behind the scenes: remote clinical trial monitoring comes of Age during the COVID-19 pandemic. JCO Oncol Pr. 2021;17:577–9.CrossRef
17.
go back to reference Jefferson T, Dooley L, Ferroni E et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev, 2023(1). Jefferson T, Dooley L, Ferroni E et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev, 2023(1).
20.
go back to reference Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Oxf). 2005;27(3):281–91.CrossRefPubMed Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Oxf). 2005;27(3):281–91.CrossRefPubMed
Metadata
Title
Concordance between SARS-CoV-2 index individuals and their household contacts on index individual COVID-19 transmission cofactors: a comparison of self-reported and contact-reported information
Authors
Angela M. Dahl
Clare E. Brown
Elizabeth R. Brown
Meagan P. O’Brien
Ruanne V. Barnabas
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18371-7

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue